RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The mandate is the latest effort in the Trump administration's push to end DEI. Employees at multiple federal agencies were ordered to remove pronouns from their email signatures by Friday ...

Multiple US government agencies have ordered employees “to remove gender identifying pronouns from email signature blocks by 5:00 PM” on Friday, according to internal emails seen by CNN.

Khaleda Rahman is Newsweek's National Correspondent based in London, UK. Her focus is reporting on abortion rights, race, education, sexual abuse and capital punishment. Khaleda joined Newsweek in ...